Teva Pharmaceutical to Acquire Barr for $7.46 Billion

Teva Pharmaceutical Industries Ltd. (Petach Tikva, Israel) says it has signed a definitive agreement to acquire specialty pharma firm Barr Pharmaceuticals (Montvale, NJ), the fourth-largest generic drug company worldwide, for about $7.46 billion. Teva will also assume Barr’s outstanding net debt of about $1.5 billion. The transaction is expected to close by year-end. Barr develops and manufactures generic and proprietary drugs, active pharma ingredients (APIs), and biopharmaceuticals. Yanai: Strengthen leadership in the U.S. The deal “will enhance our...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers